Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Company's biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation.TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused …